CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
-
D4vd used Amazon chainsaws to hack up teen's body: prosecutors
-
Meta chief Zuckerberg doubles down on AI spending
-
Saudi to end LIV Golf funding this year: reports
-
Google-parent Alphabet soars as Meta stumbles over AI costs
-
Powell's decision to stay on at Fed ignites new Trump insult
-
Brazil lowers benchmark rate to 14.5% in second consecutive cut
-
'This cannot happen': Arsenal's Arteta livid over Eze penalty review
-
Air quality improving in Europe but more effort needed: report
-
Putin, Trump discuss Iran, Ukraine in phone call: Kremlin
-
Crazy flights: Kiss frontman produces plane disaster movie
-
Google-parent Alphabet soars as rivals stumble over AI costs
-
Romanian behind 'swatting' attacks in US gets four years in prison
-
Arsenal, Atletico trade penalties in Champions League semi-final draw
-
Anti-Bezos campaign urges Met Gala boycott in New York
-
African oil producers defend need to drill at fossil fuel exit talks
-
Iran officials leave Canada before FIFA Congress over airport 'insult': Iranian media
-
Oil spikes while divided Federal Reserve keeps interest rates unchanged
-
Palace boss Glasner eager for another trophy in Europe
-
Alleged Trump assassin took selfie moments before attack: prosecutors
-
Shomrim: the Jewish volunteers protecting their community
-
Powell to bow out as Fed chief but stay as a governor on legal pressure
-
PSG blow as Hakimi ruled out of Champions League semi-final return
-
'Gritty' Philadelphia pitches itself as low-cost US World Cup choice
-
'I literally was a fool': Musk grilled in OpenAI trial
-
OpenAI facing 'waves' of US lawsuits over Canada mass shooting
-
Trump says US has 'a shot' at crewed Moon landing before presidency ends
-
Hungary's Magyar pushes to unblock EU billions in Brussels
-
London police probe 'terror' incident after two Jewish men stabbed
-
Rob Reiner autopsy report not ready, court hears
-
Rickelton ton in vain as Hyderabad chase down 244 to beat Mumbai
-
US Fed divided at Powell's likely last meeting at helm
-
Draper out of French Open in fresh injury blow
-
King Charles touts 'solidarity' with US at 9/11 memorial
-
Ticket price hikes not affecting summer air travel demand: IATA
-
Liverpool 'expect Salah to be available' before Anfield exit
-
World snooker champion Zhao Xintong succumbs to 'Crucible curse'
-
Australia FM says China agrees to collaborate on jet fuel exports
-
Pentagon chief spars with Democratic lawmakers on Iran war
-
Hungary's Magyar pushes to unblock EU billion in Brussels
-
Departing US still owes money, says WHO chief
-
Joshua warm-up defeat would 'kill' Fury fight, warns promoter Warren
-
Sinner stops Jodar to book spot in Madrid Open semis
-
Pogacar wins opening full stage to take Tour de Romandie lead
-
'River on fire': Toxic fumes as Ukrainian drones pound Russian oil town
-
Pereira aiming to bring European glory back to Forest
-
Uber adds hotel booking in push to become 'everything app'
-
Oil spikes while stocks slip ahead of US Fed rate decision
-
Two Jewish men stabbed in 'terrorist' attack in London
-
End of an era: last hereditary peers exit UK parliament
-
Canada holds key rate steady, says will act if war inflation persists
CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 8, 2025, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company's website (cnspharma.com). The webcast replay will be archived for 90 days following the event.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
H.Gonzales--AT